参考文献/References:
[1] Caforio ALP, P ankuweit S, A rbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2013, 34(33): 2636-2648.
[2] Cooper LT, Keren a, Sliwa K, et al. The global burden of myocarditis: part 1: a systematic literature review for the global burden of diseases, injuries, and risk factors 2010 study[J]. Glob Heart, 2014, 9(1): 121-129.
[3] 王志民,邹玉宝,宋雷等.超声心动图检查调查8080例成人肥厚型心肌病患病率[J].中华心血管病杂志, 2004,(12): 39-43.
[4] Schultheiss HP, Kühl U,Cooper LT. The management of myocarditis[J]. Eur Heart J, 2011, 32(21): 2616-2625.
[5] Tian Z, Zeng Y, Cheng KA, et al. Importance of endomyocardial biopsy in unexplained cardiomyopathy in China: A report of 53 consecutive patients[J]. Chin Med J, 2010, 123(7): 864-870.
[6] Pieroni M, Dello Russo A, Marzo F, et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy[J]. J Am Coll Cardiol, 2009, 53(8): 681-689.
[7] Kühl U , Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction[J]. Circulation, 2005, 111(7): 887-893.
[8] Dennert R, Velthuis S, Schalla S, et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load[J]. Antivir Ther, 2010, 15(2): 193-201.
[9] 中华医学会心血管病学分会精准医学学组. 成人暴发性心肌炎诊断与治疗中国专家共识[J]. 中华心血管病杂志, 2017, 9(45):742-752.
[10] 谷晓莹, 余淼, 廖玉华,等. 抗心肌抗体对中国扩张型心肌病诊断价值的Meta分析[J]. 临床心血管病杂志, 2016, 32(10): 1030-1038.
[11] 中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志, 2018, 34(05): 421-434.
[12] Lu C, Qin F, Yan Y, et al. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials[J]. J Cardiovasc Med (Hagerstown), 2016, 17(8): 631-637.
[13] Why HJF, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy[J]. Circulation, 1994, 89(6): 2582-2589.
[14] Stille-Siegener M, Heim A, Figulla HR. Subclassification of dilated cardiomyopathy and interferon treatment[J]. Eur Heart J, 1995, 16 Suppl O: 147-149.
[15] Fujioka S, Kitaura Y, Ukimura A, et al. Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy[J]. J Am Coll Cardiol, 2000, 36(6): 1920-1926.
[16] Caforio ALP, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: Prognostic relevance of clinical and aetiopathogenetic features at diagnosis[J]. Eur Heart J, 2007, 28(11): 1326-1333.
[17] 陈瑞珍,郭棋,王齐冰,等. 扩张型心肌病移植心脏的病毒基因检测及其随访观察[J]. 复旦学报(医学版), 2002, (02): 113-115.
[18] Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation[J]. N Engl J Med, 2001, 344(20): 1498-1503.
[19] Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis[J]. N Engl J Med, 2010, 362(13): 1248-1249.
[20] Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction[J]. Circulation, 2005, 112(13): 1965-1970.
相似文献/References:
[1]孙文静,孙林,赵新湘.心脏核磁共振在急性心肌炎中的研究进展[J].心血管病学进展,2015,(5):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
SUN Wenjing,SUN Lin,ZHAO Xinxiang.Evolution of Cardiac Magnetic Resonance Imaging in Acute Myocarditis[J].Advances in Cardiovascular Diseases,2015,(5):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
[2]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(5):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[3]张艺文 蔡琳 秦莉 杨晓倩 汪汉.基于网络药理学的参麦注射液治疗新型冠状病毒感染合并心肌炎的机制研究[J].心血管病学进展,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
ZHANG YiwenCAI LinQIN LiYANG XiaoqianWANG Han.Shenmai Injection for COVID-19 with Myocarditis Based on Network Pharmacology[J].Advances in Cardiovascular Diseases,2020,(5):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
[4]杨晓倩 秦莉 张艺文 汪汉.苦参治疗新型冠状病毒感染合并心肌炎的网络药理学分析[J].心血管病学进展,2021,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Network Pharmacological Analysis of Sophora Flavescens on Novel Coronavirus Infection complicated with Myocarditis[J].Advances in Cardiovascular Diseases,2021,(5):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
[5]肖乾凤 王斯 刘燕扬 魏欣.免疫检查点抑制剂相关性心肌炎的诊治[J].心血管病学进展,2022,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
Inhibitors-Related Myocarditis.Diagnosis and Treatment of Immune Checkpoint[J].Advances in Cardiovascular Diseases,2022,(5):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(5):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
[7]朱煜欣 王天博 刘晓翰 张悦 何韵 黄刚 徐俊波.炎症性心肌病的机制及治疗进展[J].心血管病学进展,2024,(4):317.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.007]
ZHU Yuxin,WANG Tianbo,LIU Xiaohan,et al.Advances in the Pathogenesis and Treatment of Inflammatory Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(5):317.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.007]
[8]王斯 魏欣 肖乾凤 陈晓平.心肌炎的分类及治疗进展[J].心血管病学进展,2021,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
WANG Si,WEI Xin,XIAO Qianfeng,et al.The Classification and Treatment Progress of Myocarditis[J].Advances in Cardiovascular Diseases,2021,(5):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]